In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
Tumor angiogenesis and lymphangiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer (NSCLC). Bevacizumab, which is a monoclonal antibody, was the initial inhibitor of angiogenesis and lymphangiogenesis that received approval for use in the treatment...
| Main Authors: | , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
MDPI AG
2023-07-01
|
| 叢編: | Biomedicines |
| 主題: | |
| 在線閱讀: | https://www.mdpi.com/2227-9059/11/7/2011 |